| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B
Kinase That Enhances Cellular Apoptosis and Inhibits Cellular Invasion through Suppression of NF-B-Regulated Gene Products1
* Cytokine Research Section, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; and Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
B, we postulated that ACA might mediate its activity through modulation of NF-B activation. For this report, we investigated the effect of ACA on NF-B and NF-B-regulated gene expression activated by various carcinogens. We found that ACA suppressed NF-B activation induced by a wide variety of inflammatory and carcinogenic agents, including TNF, IL-1
, PMA, LPS, H2O2, doxorubicin, and cigarette smoke condensate. Suppression was not cell type specific, because both inducible and constitutive NF-B activations were blocked by ACA. ACA did not interfere with the binding of NF-B to the DNA, but, rather, inhibited IB
kinase activation, IB phosphorylation, IB degradation, p65 phosphorylation, and subsequent p65 nuclear translocation. ACA also inhibited NF-B-dependent reporter gene expression activated by TNF, TNFR1, TNFR-associated death domain protein, TNFR-associated factor-2, and IB kinase, but not that activated by p65. Consequently, ACA suppressed the expression of TNF-induced NF-B-regulated proliferative (e.g., cyclin D1 and c-Myc), antiapoptotic (survivin, inhibitor of apoptosis protein-1 (IAP1), IAP2, X-chromosome-linked IAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP), and metastatic (cyclooxygenase-2, ICAM-1, vascular endothelial growth factor, and matrix metalloprotease-9) gene products. ACA also enhanced the apoptosis induced by TNF and chemotherapeutic agents and suppressed invasion. Overall, our results indicate that ACA inhibits activation of NF-B and NF-B-regulated gene expression, which may explain the ability of ACA to enhance apoptosis and inhibit invasion. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
For reasons detailed below, we postulated that ACA mediates its various activities through suppression of the transcription factor NF-B. First, NF-B is activated by various carcinogens, tumor promoters, and tumor microenvironment (hypoxia and acidic pH). Second, most inflammatory agents activate NF-B. Third, NF-B regulates the expression of genes that regulate transformation, tumor promotion, tumor invasion, angiogenesis, and metastasis. Fourth, suppression of apoptosis is regulated by NF-B. And fifth, chemopreventive agents have been shown to suppress NF-B activation (15).
NF-B is a heterodimeric protein complex of members of the Rel (p50)/NF-B (p60) protein family. NF-B is primarily composed of proteins with molecular masses of 50 kDa (p50) and 65 kDa (p65) and is retained in the cytoplasm by inhibitory subunit, IB (16). In its unstimulated form, NF-B is activated by a wide variety of inflammatory stimuli, including TNF, IL-1, PMA, H2O2, endotoxin, and gamma irradiation. Most of these agents induce the phosphorylation-dependent degradation of IB proteins, allowing active NF-B to translocate to the nucleus, where it regulates gene expression. The phosphorylation of IB is mediated through the activation of the IB kinase (IKK) complex consisting of IKK-, IKK-, IKK-
(also called NEMO), IKK-associated protein-1, 14,700-kDa-interacting protein-3 (FIP-3) (type 2 adenovirus E3–14.7kDa interacting protein), 90-kDa heat shock protein, and glutamic acid (E), leucine (L), lysine (K), and serine (S)-abundant protein (ELKS) (17).
Because of the critical role of NF-B in proliferative and inflammatory diseases, we investigated the effect of ACA on NF-B activation induced by carcinogens, tumor promoters, and inflammatory agents. The results described below strongly suggest that ACA is a potent suppressor of NF-B activation induced by various agents and that this suppression is mediated through inhibition of IKK. As a result, the expression of gene products that regulate apoptosis, proliferation, angiogenesis, and invasion is suppressed.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
ACA was synthesized as previously described (18). A 50-mM solution of ACA was prepared with DMSO, stored as small aliquots at –20°C, and then diluted as needed in cell culture medium. Bacteria-derived human recombinant human TNF, purified to homogeneity with a specific activity of 5 x 107 U/mg, was provided by Genentech. Cigarette smoke condensate, prepared as previously described (19), was supplied by Dr. G. Gairola (University of Kentucky, Lexington, KY). Penicillin, streptomycin, RPMI 1640 medium, and FBS were obtained from Invitrogen Life Technologies. PMA, okadaic acid, H2O2, and anti--actin Ab were obtained from Sigma-Aldrich. Abs anti-p65, anti-p50, anti-IB, anti-cyclin D1, anti-matrix metalloprotease-9 (anti-MMP-9), anti-c-Myc, anti- poly(ADP-ribose) polymerase (anti-PARP), anti-inhibitor of apoptosis protein-1 (anti-IAP1), anti-IAP2, anti-Bcl-2, anti-Bcl-xL, and anti-Bfl-1/A1 were obtained from Santa Cruz Biotechnology. Anti-cyclooxygenase-2 (anti-COX-2) and anti-X-chromosome-linked IAP (XIAP) Abs were obtained from BD Biosciences. Phosphospecific anti-IB (Ser32), phosphospecific anti-p65 (Ser536), and anti-acetyl-lysine Abs were purchased from Cell Signaling. Anti-IKK-, anti-IKK-, and anti-FLIP Abs were provided by Imgenex.
Cell lines
KBM-5 (human chronic myeloid leukemia), H1299 (lung adenocarcinoma), Jurkat (human T cell lymphoma), A293 (human embryonic kidney carcinoma), and MCF-7 (human breast adenocarcinoma) cells were obtained from American Type Culture Collection. LICR-LON-HN5 and SCC4 (both human squamous cell carcinoma) cells were obtained from Dr. M. J. O’Hare (Haddow Laboratories, Institute of Cancer Research, Sutton, U.K.). KBM-5 cells were cultured in IMDM with 15% FBS. Jurkat, H1299, MM1, and U266 cells were cultured in RPMI 1640 medium, and A293 cells were cultured in DMEM supplemented with 10% FBS. LICR-LON-HN5 and SCC4 cells were cultured in DMEM containing 10% FBS, 100 µM nonessential amino acids, 1 mM pyruvate, 6 mM L-glutamine, and 1x vitamins. Culture media were also supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin.
EMSA
To determine NF-B activation, we performed EMSA as described previously (20). Briefly, nuclear extracts prepared from TNF-treated cells were incubated with 32P-end-labeled, 45-mer, double-stranded NF-B oligonucleotide (15 µg of protein with 16 fmol of DNA) from the HIV long terminal repeat, 5'-TTGTTACAA GGGACTTTC CGCTG GGGACTTTC CAGGGAGGCGTGG-3' (underlining indicates NF-B binding sites) for 30 min at 37°C, and the DNA-protein complex formed was separated from free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5'-TTGTTACAA CTCACTTTC CGCTG CTCACTTTC CAGGGAGGCGTGG-3', was used to examine the specificity of binding of NF-B to the DNA. The specificity of binding was also examined by competition with the unlabeled oligonucleotide. For supershift assays, nuclear extracts prepared from TNF-treated cells were incubated with Abs against either p50 or p65 of NF-B for 15 min at 37°C before the complex was analyzed by EMSA. Abs against preimmune serum (PIS) was included as negative controls. The dried gels were visualized, and radioactive bands were quantitated by a PhosphorImager (Molecular Dynamics) using ImageQuant software.
Western blot analysis
To determine the levels of protein expression in the cytoplasm or nucleus, we prepared extracts (21) and fractionated them by SDS-PAGE. After electrophoresis, the proteins were electrotransferred to nitrocellulose membranes, blotted with each Ab, and detected by ECL regent (Amersham Biosciences). The bands obtained were quantitated using National Institutes of Health imaging software.
IKK assay
To determine the effect of ACA on TNF-induced IKK activation, an IKK assay was performed by a method described previously (22). To determine the total amounts of IKK- and IKK- in each sample, 50 µg of the whole-cell protein was resolved on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then blotted with either anti-IKK- or anti-IKK- Abs.
NF-B-dependent reporter gene expression assay
NF-B-dependent reporter gene expression was performed as previously described (23). The effects of ACA on TNF-, TNFR-, TNFR-associated death domain protein (TRADD)-, TNFR-associated factor-2 (TRAF2)-, NF-B-inducing kinase (NIK)-, IKK--, and p65-induced NF-B-dependent reporter gene transcription were analyzed by secretory alkaline phosphatase (SEAP) assay as previously described (23). Briefly, A293 cells (5 x 105 cells/well) were plated in six-well plates and transiently transfected by FuGene6 (Roche) with pNF-B-SEAP (0.25 µg). To examine TNF-induced reporter gene expression, we transfected the cells with 0.25 µg of the SEAP expression plasmid for 24 h. Thereafter we coincubated the cells for 24 h with 10 µM ACA and 1 nM TNF for an additional 24 h. The cell culture medium was harvested after 24 h of TNF treatment and analyzed for SEAP activity essentially according to the protocol described by the manufacturer (BD Clontech) using a 96-well fluorescence plate reader (Fluoroscan II; Labsystems) with excitation set at 360 nm and emission at 460 nm.
Immunocytochemistry for NF-B p65 localization
The effect of ACA on the nuclear translocation of p65 was examined by immunocytochemistry as previously described (21).
Live and dead assay
To measure apoptosis, we also used the live and dead assay (Molecular Probes), which determines intracellular esterase activity and plasma membrane integrity. This assay was performed as previously described (24).
Cytotoxicity assay
The effect of ACA on the cytotoxic effects of TNF and chemotherapeutic agents was determined by the MTT uptake method as previously described (25).
Annexin V assay
An early indicator of apoptosis is the rapid translocation and accumulation of the membrane phospholipid phosphatidylserine from the cytoplasmic interface to the extracellular surface. This loss of membrane asymmetry can be detected using the binding properties of annexin V. To identify apoptosis, we stained cells with annexin V Ab conjugated with FITC dye. Briefly, 5 x 105 cells were coincubated with 10 µM ACA and 1 nM TNF for 16 h at 37°C and then stained. Cells were washed in PBS, resuspended in 100 µl of binding buffer containing FITC-conjugated anti-annexin V Ab, and then analyzed by flow cytometer (FACSCalibur; BD Biosciences).
TUNEL assay
We also assayed cytotoxicity by the TUNEL method, which examines DNA strand breaks during apoptosis, using an in situ cell death detection reagent (Roche). Briefly, 5 x 105 cells were coincubated with 10 µM ACA and 1 nM TNF for 16 h at 37°C. Thereafter, cells were incubated with reaction mixture for 60 min at 37°C. Stained cells were analyzed by flow cytometer (FACSCalibur; BD Biosciences).
Invasion assay
Invasion through the extracellular matrix is a crucial step in tumor metastasis. We used Matrigel basement membrane matrix extracted from the Englebreth-Holm-Swarm mouse tumor as a reconstituted basement membrane for in vitro invasion assays. The BD BioCoat tumor invasion system we used has a chamber with a light-tight polyethelyene terephlate membrane with 8-µm pores coated with a reconstituted basement membrane gel (BD Biosciences). We resuspended 2.5 x 104 H1299 cells in serum-free medium and seeded the suspension into the upper wells. After incubation overnight, cells were coincubated with 10 µM ACA and TNF for an additional 24 h in the presence of 1% FBS. The cells that passed through the Matrigel were labeled with 4 µg/ml calcein AM (Molecular Probes) in PBS for 30 min at 37°C and subjected to scan fluorescence by a Vector 3 luminometer (PerkinElmer).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
B activation pathway induced by various carcinogens and inflammatory stimuli and on NF-B-regulated gene expression. Because the TNF-induced NF-B activation pathway has been well characterized, we investigated in detail the effects of ACA on TNF-induced NF-B activation. The structure of ACA is shown in Fig. 1A.
|
B activation induced by carcinogens-tumor promoters and inflammatory agents
Because TNF, PMA, LPS, IL-1, doxorubicin (DOX), H2O2, and cigarette smoke condensate (CSC) are potent activators of NF-B (19, 25, 26, 27), we examined the effect of ACA on the activation of NF-B by these agents. Coincubation of cells with 50 µM ACA suppressed the activation of NF-B induced by all seven agents (Fig. 1B). The concentration of ACA and NF-B activators used and the time of exposure had minimal effect on cell viability. These results suggest that ACA acts at a step in the NF-B activation pathway that is common to all seven agents.
Inhibition of NF-B activation by ACA is dose dependent
Because TNF is one of the most potent activator of NF-B, and the mechanism of activation of NF-B is relatively well established (28), we examined the effects of different doses of ACA on TNF-induced NF-B activation in human myeloid KBM5 cells. Cells were exposed to different concentrations of ACA together with TNF for 30 min and then examined for NF-B activation. These studies indicated that ACA suppressed TNF-induced NF-B activation in a dose-dependent manner, with 60% inhibition at 10 µM and almost 100% inhibition at 50 µM (Fig. 2A).
|
B activation by ACA is not cell type specific
Because the signal transduction pathway mediated by NF-B may be distinct in different cell types (29, 30), we investigated whether ACA could block TNF-induced NF-B activation in breast adenocarcinoma MCF-7 (Fig. 2B), human T cell lymphoma Jurkat (Fig. 2B), and human lung carcinoma H1299 cells (Fig. 2B). These cells were exposed to TNF in the presence or the absence of ACA for 30 min and then examined for NF-B activation. TNF activated NF-B in every cell type, and ACA completely inhibited most of this activation, indicating that ACA-induced suppression of NF-B activation was not cell type specific.
ACA also suppresses constitutive NF-B activation
Most tumor cells express constitutively active NF-B (26, 27), although the mechanism is not well understood. We showed that ACA suppresses constitutive activation of NF-B in human multiple myeloma (MM1 and U266) and head and neck squamous cell carcinoma (SCC4 and HN5) cells, which are known to express constitutive active NF-B (31, 32) (Fig. 2C).
ACA is a fast-acting inhibitor of NF-B activation
The suppression of NF-B by most agents, including TNF, requires that they be applied before the NF-B-activating agent (21, 24). However, treatment with ACA 5 min before TNF treatment,at the same time as TNF treatment, or 5 or 10 min after TNF treatment all suppressed TNF-induced NF-B activation (Fig. 3A), suggesting that ACA is a fast-acting inhibitor of NF-B activation.
|
B subunits
Various combinations of Rel/NF-B protein constitute active NF-B heterodimers, p50 and p65, that bind to a specific DNA sequence (16). When we incubated nuclear extracts from TNF-stimulated cells with Abs to either the p50 (NF-B1) or the p65 (RelA) subunit of NF-B, each shifted the band to a higher molecular mass (Fig. 3B). PIS had no effect on the binding. Abs alone did not directly interact with the labeled probe (data not shown). Thus, the TNF-activated complex consisted of p50 and p65 subunits. Additionally, excess unlabeled NF-B caused complete disappearance of the band, but a mutant oligonucleotide of NF-B did not affect NF-B binding activity.
ACA does not directly interfere with binding of NF-B to DNA
Several NF-B inhibitors have been shown to suppress NF-B activation by directly blocking the binding of NF-B to the DNA (33, 34, 35). When we incubated nuclear extracts from TNF-treated cells with ACA, EMSA showed that ACA had no direct effect on NF-B binding to the DNA (Fig. 3C). Thus, ACA must inhibit NF-B activation through an indirect mechanism.
ACA is a potent inhibitor of NF-B activation
To determine the effect of ACA on NF-B activation at higher concentrations, cells were treated with the indicated concentrations of TNF for 30 min in the absence or the presence of ACA and then analyzed NF-B activation by EMSA (Fig. 3D). TNF at a concentration of 10 nM activated NF-B activity strongly, and ACA abolished TNF-induced NF-B activation. These results show that ACA is a very potent inhibitor of TNF-induced NF-B activation.
ACA inhibits TNF-dependent IB degradation
We examined ACA- and TNF-treated cells for NF-B by EMSA and for IB by Western blot analysis. TNF-induced NF-B activation was completely suppressed by ACA (Fig. 4A). ACA also suppressed TNF-induced IB degradation, although not completely (Fig. 4B). These results indicate that ACA inhibits both TNF-induced NF-B activation and IB degradation.
|
As shown in Fig. 4C, Western blot analysis indicated that ACA significantly inhibited TNF-induced nuclear translocation of p65. Immunocytochemistry appeared to confirm this (Fig. 4D).
ACA inhibits TNF-dependent IB phosphorylation
Because IB phosphorylation is needed for IB degradation, we determined whether ACA modulated IB phosphorylation. Because TNF-induced phosphorylation of IB leads to its rapid degradation, we blocked IB phosphorylation and degradation with the proteasome inhibitor N-Ac-leu-leu-norleucinal (ALLN). Western blot analysis using an Ab specific for the serine-phosphorylated form of IB showed that ACA suppressed TNF-induced phosphorylation of IB (Fig. 5A).
|
TNF also induces the phosphorylation of p65, which is required for its transcriptional activity (16). As shown in Fig. 5B, the coincubation of cells with ACA consistently inhibited TNF-induced phosphorylation of p65.
ACA inhibits TNF-induced IKK activation
IKK is required for TNF-induced phosphorylation of IB (17), and the phosphorylation of p65 requires IKK activation (36). Because ACA inhibited the phosphorylation of both IB and p65, we determined its effect on TNF-induced IKK activation. Immune complex kinase assays show that ACA suppressed the activation of IKK by TNF (Fig. 5C). Neither TNF nor ACA had any effect on the expression of IKK- or IKK- proteins. To evaluate whether ACA suppresses IKK activity directly by binding to the IKK protein or by suppressing the activation of IKK, we incubated whole-cell extracts from untreated and TNF-treated cells with various concentrations of ACA. An immune complex kinase assay showed that ACA did not directly affect the activity of IKK, suggesting that ACA modulates TNF-induced IKK activation (Fig. 5D).
ACA represses TNF-induced NF-B-dependent reporter gene expression
Because DNA binding does not always correlate with NF-B-dependent gene transcription (37), we investigated the effect of ACA on TNF-induced reporter activity. Cells transiently transfected with the NF-B-regulated SEAP reporter construct, incubated with ACA, and then stimulated with TNF had significantly diminished reporter gene expression (Fig. 6). These results suggest that ACA inhibited TNF-induced gene expression.
|
B activation induced by TNFR1, TRADD, TRAF2, NIK, and IKK
TNF-induced NF-B activation is mediated through sequential interaction of the TNFR with TRADD, TRAF2, NIK, and IKK, resulting in phosphorylation of IB (38, 39). When we transiently transfected cells with the NF-B-regulated SEAP reporter construct along with TNFR1-, TRADD-, TRAF2-, NIK-, IKK--, or p65-expressing plasmids; treated them with ACA; and then monitored NF-B-dependent SEAP expression, we found that ACA suppressed NF-B activation induced by TNFR1, TRADD, TRAF2, NIK, and IKK-, but not that induced by p65 (Fig. 6). These results suggested that ACA acts at a step upstream from p65.
ACA represses the TNF-induced NF-B-dependent gene products involved in cell proliferation
Cyclin D1 is overexpressed in a wide variety of tumors and mediates the progress of cells from G1 to S phase (40). Similarly, COX-2 is overexpressed in tumor cells and mediates proliferation (41). The role of c-Myc in the proliferation of tumor is well established (42). The expression of all three genes is regulated by NF-B (43, 44, 45). We found that ACA also blocked the expression of these genes (Fig. 7A). These results further strengthen our postulate that ACA blocks TNF-induced, NF-B-regulated gene products.
|
B-dependent gene products involved in angiogenesis and metastasis
The roles of vascular endothelial growth factor (VEGF), MMP-9, and ICAM-1 in angiogenesis and metastasis of tumors are well established. All three gene products are also regulated by NF-B (46, 47, 48), so we investigated the effect of ACA on this regulation. Western blot analysis (Fig. 7B) showed that ACA blocked TNF-induced VEGF, ICAM-1. and MMP-9 protein expression in a time-dependent manner. These results suggest that ACA plays a role in suppressing angiogenesis and metastasis.
ACA represses TNF-induced, NF-B-dependent antiapoptotic gene products
NF-B regulates the expression of the antiapoptotic proteins, survivin (49), IAP1/2 (50, 51), XIAP (52), Bcl-2 (53, 54, 55), Bcl-xL (56), Bfl-1/A1 (57, 58), and FLIP (59), so we examined whether ACA can modulate the expression of these antiapoptotic gene products induced by TNF. As shown in Fig. 7C, ACA blocked the expression of these TNF-induced, antiapoptotic proteins.
ACA potentiates apoptosis induced by TNF and chemotherapeutic agents
The activation of NF-B can inhibit TNF-induced apoptosis (60, 61, 62, 63, 64), so we determined the potential of ACA to enhance apoptosis induced by TNF and other cytotoxic agents. We used the live and dead assay, MTT, PARP cleavage, annexin V staining, and TUNEL staining methods. We first established that ACA enhanced the cytotoxicity induced by TNF (Fig. 8A1), cisplatin (Fig. 8A2), DOX (Fig. 8A3), and taxol (Fig. 8A4). ACA by itself had little cytotoxic effect. Next, we showed that ACA enhanced cytotoxicity by potentiating TNF-induced apoptosis. As shown in Fig. 8B, ACA potentiated the TNF activation of caspases, as indicated by the PARP cleavage assay. The live and dead assay indicated that ACA up-regulated TNF-induced cytotoxicity from 2 to 51% (Fig. 8C), and annexin V staining indicated that ACA up-regulated TNF-induced early apoptosis (Fig. 8D). TUNEL staining showed that TNF-induced apoptosis was enhanced by incubation with ACA (Fig. 8E). In this assay, ACA alone exhibited slight toxicity. The results of all the assays taken together suggest that ACA enhanced cytotoxicity by enhancing the apoptotic effects of TNF, cisplatin, taxol, and DOX.
|
MMPs, COXs, and adhesion molecules that are regulated by NF-B have been shown to mediate tumor invasion (65), and TNF can induce the expression of genes involved in tumor metastasis (66). Whether ACA modulates TNF-induced invasion activity in vitro was examined. For this study, we used H1299 cells seeded in the top chamber of a Matrigel invasion chamber in the absence of serum. Cells were coincubated with TNF in the presence or the absence of ACA for 24 h. As shown in Fig. 9, TNF induced cell invasion activity, and ACA suppressed it.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
B activation. In the present study we found that ACA did indeed inhibit NF-B activated by a variety of agents and in a variety of cell lines. In detail, NF-B activity was inhibited because ACA suppressed IKK activation, thus resulting in inhibition of IB phosphorylation and degradation. As a result, ACA also blocked p65 phosphorylation, p65 nuclear translocation, and NF-B-dependent reporter gene transcription. It suppressed NF-B-regulated reporter gene transcription and gene products involved in cell proliferation (e.g., cyclin D1, COX-2, and c-Myc), antiapoptosis (e.g., survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP), angiogenesis (e.g., VEGF), and invasion (e.g., MMP-9 and ICAM-1). Suppression of NF-B by ACA enhanced the apoptosis induced by TNF and chemotherapeutic agents.
Our results indicate that ACA inhibits NF-B activation instantly, because suppression was noted even when it was added after initiation of NF-B activation by TNF. In this respect, ACA-induced suppression of NF-B activation differs from that induced by curcumin (67), flavopiridol (36), and farnesyl transferase inhibitors (68). The latter requires preincubation for several hours before activating the cells for NF-B. It is unlikely that the rapid mode of action of ACA is due to its solubility in organic solvents. Whether the acetyl group in ACA has any role in the speed of its action is unclear at present.
We found that ACA inhibited NF-B activation induced by highly diverse stimuli, including inflammatory stimuli (TNF, LPS, IL-1, and H2O2), tumor promoters (PMA), chemotherapeutic agents (e.g., DOX), and carcinogens (e.g., CSC). Most of these agents activate NF-B through different pathways (15, 16, 17). For instance, we have reported that pathway for H2O2-induced NF-B activation differs from that of TNF (21). Because NF-B activated by all the agents tested was inhibited, ACA must suppress activation at a step common to all these activators. Various tumor cells express a constitutively activated form of NF-B through a mechanism that is not fully understood (15). ACA also suppressed constitutive activation. Unlike some other inhibitors (33, 34, 35), however, ACA did not modify the NF-B proteins to prevent their binding to DNA. Because TNF-induced phosphorylation and degradation of IB were also inhibited by ACA, it suggested that this agent mediates its effect through IKK, the kinase needed for IB phosphorylation. We found that ACA indeed inhibited TNF-induced activation of IKK. These results are consistent with our previous report that ACA inhibits LPS- plus IFN--induced IB degradation in RAW264.7 mouse macrophages (69). However, we show that ACA does not directly inhibit IKK activity. It is possible that this inhibition is the result of inhibition of an upstream kinase. Previous studies (70) have reported that Akt can associate with and activate IKK-. Thus, it is possible that ACA suppresses TNF-induced Akt activation.
TNF-induced NF-B activation involves the sequential interaction of TNFR with TRADD and TRAF2, which then activate IKK, leading to NF-B activation. ACA suppressed NF-B activation induced by TNFR1, TRADD, TRAF2, NIK, and IKK-, but not that activated by p65. This suggests that ACA acts at a step downstream from IKK and upstream from p65, consistent with above findings that ACA may modulate IKK.
In our study, ACA down-regulated the expression of NF-B-regulated gene products involved in cell proliferation (e.g., cyclin D1 and c-Myc) antiapoptosis (e.g., survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-xL, Bfl-1/A1, and FLIP) and invasion (MMP-9, COX-2, and ICAM-1). The down-regulation of COX-2 by ACA is consistent with a previous report that showed suppression of COX-2 expression induced by LPS/IFN- in mouse macrophages (69). Our results may also explain the down-regulation of inducible NO synthase expression (14), which is also regulated by NF-B.
We found that ACA potentiates the apoptotic effects of TNF and chemotherapeutic agents. It is very likely that this potentiation is mediated through the suppression of antiapoptotic gene products regulated by NF-B.
ACA alone has been shown to induce apoptosis in different cell types (10, 11, 12), and this may also be linked to the suppression of NF-B. ACA suppressed TNF-induced tumor invasion. Invasion and metastasis require the expression of MMP-9, COX-2, and ICAM-1, all of which are modulated by ACA. VEGF, a potent angiogenic factor, is also down-regulated by ACA. These results thus suggest that ACA may be effective not only as a chemopreventive agent, but also as a therapeutic agent, through regulation of various mechanisms, as indicated above.
Overall, our results demonstrated that ACA has potent antiproliferative, proapoptotic, antimetastatic, anti-inflammatory, and immunomodulatory effects, all mediated through NF-B activation (Fig. 10). They set the stage for preclinical studies to establish the potential of ACA for clinical trial.
|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported by the Clayton Foundation for Research (to B.B.A.), Department of Defense U.S. Army Breast Cancer Research Program Grant BC010610 (to B.B.A.), PO1 Grant CA91844 from the National Institutes of Health on lung chemoprevention (to B.B.A.), a P50 Head and Neck SPORE grant from the National Institutes of Health (P50CA97007 to B.B.A.). 
2 Address correspondence and reprint requests to Dr. Bharat B. Aggarwal, Cytokine Research Section, Department of Experimental Therapeutics, Box 143, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail address: aggarwal{at}mdanderson.org
3 Abbreviations used in this paper: ACA, 1'-acetoxychavicol acetate; ALLN, N-Ac-leu-leu-norleucinal; COX, cyclooxygenase; CSC, cigarette smoke condensate; DOX, doxorubicin; IAP, inhibitor of apoptosis protein; IKK, IB kinase; MMP, matrix metalloproteinase; PARP, poly(ADP-ribose) polymerase; PIS, preimmune serum; SEAP, secretory alkaline phosphatase; TRADD, TNFR-associated death domain protein; TRAF, TNFR-associated factor; VEGF, vascular endothelial growth factor; XIAP, X-chromosome-linked IAP; NIK, NF-B-inducing kinase.
Received for publication November 5, 2004. Accepted for publication March 22, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-induced nitric oxide production through suppression of inducible nitric oxide synthase gene expression in RAW264 cells. Carcinogenesis 19: 1007-1012.B: the enemy within. Cancer Cell. 6: 203-208.[Medline]
B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225-260.[Medline]
B requires ELKS, an IB kinase regulatory subunit. Science 304: 1963-1967.B through phosphorylation and degradation of IB(): correlation with induction of cyclooxygenase-2. Carcinogenesis 23: 1511-1518.B through tyrosine phosphorylation of IB and serine phosphorylation of p65: evidence for the involvement of IB kinase and Syk protein-tyrosine kinase. J. Biol. Chem. 278: 24233-24241. suppresses activation of nuclear transcription factors NF-B and activator protein 1 and potentiates TNF-induced apoptosis. J. Immunol. 165: 4927.B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-B-inducing kinase: identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274: 7724-7731.B activation induced by various inflammatory stimuli and its role in down-regulation of NF-B-mediated gene expression and up-regulation of apoptosis. J. Biol. Chem. 279: 15096-15104.B activation induced by carcinogenic agents through suppression of IB kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 63: 4375-4383.B transcription factors. Oncogene 18: 6853-6866.[Medline]
B induction by IL-1 in epithelial and lymphoid cells. J. Immunol. 159: 5264-5272.[Abstract]
B puzzle. Cell 109:(Suppl): S81-S96.
B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184.B signaling. Int. J. Cancer 111: 679-692.[Medline]
B. Proc. Natl. Acad. Sci. USA 93: 9090-9095.B activation in T lymphocytes: evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270: 28557-28564.B is not sufficient for its dissociation from NF-B and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA 91: 11884-11888.B activation induced by various carcinogens and inflammatory agents through inhibition of IB kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J. Biol. Chem. 279: 4750-4759.B kinase activation and IB degradation by interleukin-1 and tumor necrosis factor- in human U937 monocytic cells: evidence for additional regulatory steps in B-dependent transcription. J. Biol. Chem. 274: 19965-19972.B proteins control NF-B activity. Proc. Natl. Acad. Sci. USA 96: 49-54.B activation. Cell 81: 495-504.[Medline]
B and nuclear factor-interleukin-6 in the tumor necrosis factor -dependent induction of cyclooxygenase-2 in MC3T3–E1 cells. J. Biol. Chem. 270: 31315-31320.B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19: 5785-5799.-mediated up-regulation of HIF-1 via an NFB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17: 2115-2117.-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-B. J. Biol. Chem. 277: 35766-35775.B-independent manner. EMBO J. 22: 1567-1578.[Medline]
B control. Proc. Natl. Acad. Sci. USA 94: 10057-10062.B-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor -induced apoptosis. J. Exp. Med. 188: 211-216.B and its significance in prostate cancer. Oncogene 20: 7342-7351.[Medline]
B, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor -evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1. Cancer Res. 64: 9041-9048.B activation in primary hippocampal neurons. J. Biol. Chem. 274: 8531-8538.B that blocks TNF-induced apoptosis. Genes Dev. 13: 382-387.B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21: 3964-3973.B-dependent transcription by tumor necrosis factor- is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 273: 29411-29416.B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 273: 14008-14014.B activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812-1815.-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone: functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 269: 6185-6192.B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270: 24995-25000.B activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-B-regulated gene expression and up-regulation of apoptosis. J. Biol. Chem. 279: 26287-26299.-induced IB degradation in RAW264.7 macrophages. Cancer Lett. 195: 17-25.[Medline]
B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.[Medline]This article has been cited by other articles:
|
|
 |
|
  P. Anand, A. B. Kunnumakkara, K. B. Harikumar, K. S. Ahn, V. Badmaev, and B. B. Aggarwal Modification of Cysteine Residue in p65 Subunit of Nuclear Factor-{kappa}B (NF-{kappa}B) by Picroliv Suppresses NF-{kappa}B-Regulated Gene Products and Potentiates Apoptosis Cancer Res., November 1, 2008; 68(21): 8861 - 8870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Kunnumakkara, H. Ichikawa, P. Anand, C. J. Mohankumar, P. S. Hema, M. S. Nair, and B. B. Aggarwal Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-{kappa}B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis Mol. Cancer Ther., October 1, 2008; 7(10): 3306 - 3317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Kunnumakkara, A. S. Nair, K. S. Ahn, M. K. Pandey, Z. Yi, M. Liu, and B. B. Aggarwal Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-{kappa}B activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis Blood, June 15, 2007; 109(12): 5112 - 5121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Brown, D. Tan, J. S. Taylor, M. Miller, J. W. Prichard, and M. M. Kott Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-kappaB Pathways in High Risk Neuro-blastoma, with Cell Cycle and Protein Analyte Correlates Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells Mol. Cancer Res., October 1, 2006; 4(10): 715 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ichikawa, M. S. Nair, Y. Takada, D.B. A. Sheeja, M.A. S. Kumar, O. V. Oommen, and B. B. Aggarwal Isodeoxyelephantopin, a Novel Sesquiterpene Lactone, Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis through Suppression of Nuclear Factor-{kappa}B (NF-{kappa}B) Activation and NF-{kappa}B-Regulated Gene Expression. Clin. Cancer Res., October 1, 2006; 12(19): 5910 - 5918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Sandur, H. Ichikawa, G. Sethi, K. S. Ahn, and B. B. Aggarwal Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-{kappa}B Activation and NF-{kappa}B-regulated Gene Products Through Modulation of p65 and I{kappa}B{alpha} Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents J. Biol. Chem., June 23, 2006; 281(25): 17023 - 17033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ichikawa, Y. Takada, S. Shishodia, B. Jayaprakasam, M. G. Nair, and B. B. Aggarwal Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-{kappa}B (NF-{kappa}B) activation and NF-{kappa}B-regulated gene expression. Mol. Cancer Ther., June 1, 2006; 5(6): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ichikawa, A. Murakami, and B. B. Aggarwal 1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation Mol. Cancer Res., April 1, 2006; 4(4): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal Acetyl-11-Keto-beta-Boswellic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing NF-{kappa}B and NF-{kappa}B-Regulated Gene Expression. J. Immunol., March 1, 2006; 176(5): 3127 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ichikawa and B. B. Aggarwal Guggulsterone Inhibits Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor-{kappa}B Ligand and by Tumor Cells by Suppressing Nuclear Factor-{kappa}B Activation Clin. Cancer Res., January 15, 2006; 12(2): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
